Doxorubicin transferrin conjugate - Panther Biotechnology

Drug Profile

Doxorubicin transferrin conjugate - Panther Biotechnology

Alternative Names: Doxorubicin transferrin conjugate - Faulk Pharmaceuticals; FP TD1; Transferrin Doxorubicin; TRF DOX

Latest Information Update: 14 Dec 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Faulk Pharmaceuticals
  • Developer Panther Biotechnology
  • Class Anthracyclines; Cytostatic antibiotics; Doxorubicins; Drug conjugates; Small molecules
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Ovarian cancer

Highest Development Phases

  • Clinical Phase Unknown Haemangiosarcoma; Leukaemia; Ovarian cancer

Most Recent Events

  • 13 Dec 2016 Doxorubicin transferrin conjugate - Panther Biotechnology is available for licensing for phase IIa development as of 07 Dec 2016. http://pantherbiotechnology.com/
  • 07 Dec 2016 Doxorubicin transferrin conjugate receives positive feedback from US FDA for clinical development in Ovarian cancer
  • 25 Oct 2016 The US FDA grants approval for pre-IND meeting to Panther biotechnology with centre for drug evaluation and research (CDER) of the US FDA for doxorubicin transferrin conjugate in Ovarian cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top